Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction

Summary

This is a double-blind, randomized, parallel group, dose ranging study of subcutaneous methylnaltrexone to be conducted in patients with advanced medical illness and poorly controlled opioid induced constipation. Patients will be randomized to one of three fixed dose levels of SC MNTX.

Timeline

Start

2002-04

Primary completion

2003-05

Completion

2003-05

Drugs

Indications